Close Menu

respiratory infection

GenMark said its ePlex molecular diagnostic product revenue for Q4 was $45.4 million, an increase of 138 percent over the fourth quarter of 2019.

The two firms aim to bring down costs and turnaround time with two newly-launched sequencing tests for respiratory pathogens, RVOP 2 and Explify RPIP.

Qiagen received CE IVD marking for its NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test and for a saliva collection kit for its single-plex NeuMoDx SARS-CoV-2 assay.

The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.

The test is designed to measure the expression of IFI27, a gene strongly correlated with disease progression in influenza and COVID-19.

The company's system revenues were up 28 percent to $19.5 million and consumables revenues dropped 12 percent to $11.8 million.

The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.

The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.

The company said that the FDA has granted it Emergency Use Authorization for a respiratory panel that includes SARS-CoV-2, flu, and other pathogens.

BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.

Pages

SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.

The New York Times reports that a new viral variant of concern has been identified in New York City.

In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.